The application of machine learning models in predicting antimicrobial resistance with genomic data: the opportunities and challenges

Student: Bella, Liuyue Yang (2<sup>nd</sup> year MPhil) Supervisor: Prof. Margaret Ip Joint postgraduate seminar 13 Dec 2022

# Outline

# 1. Introduction

- Antimicrobial resistance (AMR)
- Machine learning (ML) problem

2. Development and application- the GenTB predictor

3. Opportunities and challenges

# I. Antimicrobial resistance (AMR)

- A global threat to human health
- Spreading in different settings (hospitals, communities, and farms)
- Causing infections that are difficult, and sometimes impossible to treat.

-> Improve the antibiotic prescription

3

#### S1: Background

# II. Antimicrobial susceptibility testing (AST)

## - in vitro phenotypic AST methods

- Gold standard
- Labour-intense and time-consuming (slow-growing bacteria)
- Turnaround time: from days to weeks

## **III. Alternative: sequenced-based machine learning**

**Machine learning question:** development of supervised machine learning (ML) models.

**1)** Qualitative: Is an isolate resistant or susceptible to one/several antibiotics?

-> Machine learning model for classification problem (binary).

**2) Quantitative:** Predict the exact value of minimum inhibitory concentration (MIC)

-> Machine learning model for regression problem (continuous) e.g. linear regression, random forest, and lasso regression

(Anahtar et al, 2021)

# **Type 1: Machine learning models for classification**

- 1. Decision tree
- 2. Random forest (i.e. a collection of decision tree)
- 3. Logistic regression
- 4. Naïve Bayes
- 5. Support vector machines
- 6. Artificial neural networks



# **Type 1: Machine learning models for classification**



- 1. Decision tree
- 2. Random forest
- 3. Naïve Bayes
- 4. Logistic regression
- 5. Support vector machines
- 6. Artificial neural networks

How to choose model?

- 1. Ability handling missing values
- 2. Sensitivity to outlier data
- 3. Interpretability
- 4. Speed of learning

S2: Model development and applications

## **Step 1: Featurization – "feature extraction"**

Aim: to capture variation in the genomic data

- Presence or absence of genes
- Single nucleotide variants (SNVs)

e.g. single nucleotide polymorphism (e.g. SNPs)

- Insertion or deletion of bases (Indels)

#### **Featurization methods:**

- *k*-mers-based modelling (presence/absence or frequency of each *k*-mer)
- Alignment-based or functional orthologs-based

S2: Model development and applications

## **Step 2: a routine supervised machine learning model**

Labels (Phenotype): R or S ("ground truth")

**Train data and test data:** DNA sequence + labels

## **Model validation**

- Independent dataset (e.g. external)
- Performance indicator:
  - **Specificity** (true positive rate)
  - Sensitivity (true negative rate)
  - ROC curve (receiver operating characteristic curve) and
    AUC (area under the ROC curve)

- Target bacteria: *Mycobacterium tuberculosis* 

Treatment barrier: Diagnosing drug resistance

- Culture-based method: grow slowly
- Long turnaround time: *In vitro* antibiotic susceptibility tests (AST)
- PCR-based method: limited drugs and poor detection accuracy
- WGS becomes more affordable

- Target bacteria: *Mycobacterium tuberculosis*
- Open and web-based prediction tool
- Phenotypic prediction for 10 to 13 antibiotics, such as rifampicin and amikacin

- User-friendly: for non-expert user
- Batch upload: up to 300 isolates
- Pre-processing of the dataset (e.g. quality check)
- Computing time (median): 35 mins
- Get email when prediction results are ready

https://gentb.hms.harvard.edu

- **Two multivariate machine learning models** (random forest & wide and deep neural network)
- Trained with rich variants dataset
- Empowered by two machine learning models

### Model 1: Random forest

Training dataset: 1,397 strains

Featurization: alignment

Features: 238 mutations (i.e. SNPs, deletion, and insertion)

#### Model 2: Wide and deep neural network

Input - training dataset: 3,601 strains Featurization: alignment Features: 222 mutations (i.e. SNPs, deletion, and insertion)

(Gröschel et al, 2021; Chen et al, 2019; Farhat et al, 2016)

# **Example - GenTB: a predictor for tuberculosis resistance** Performance validation:

- A ground truth dataset of **20,408 isolates**
- **Indicators**: sensitivity, specificity, and AUC.
- High prediction accuracy to first-line tuberculosis drugs (rifampicin and isoniazid)
- Lower prediction accuracy to second-line tuberculosis drugs (low sensitivity), such as amikacin.
- **Reasons for prediction bias**: undescribed resistance variants in training dataset, undetected genetic loci, and the reproducibility of AST results.

- Performance validation compared with other predictors:
  - **Rule-based model:** Mykrobe and TB-Profiler
  - Test data: A ground truth dataset of 20,408 isolates

	Sensitivity (True negative)	Specificity (True positive)
GenTB-RF	77.6% (95% CI 76.6–78.5%)	96.1% (95% CI 96.0 – 96.3%)
GenTB-WDNN	75.4% (95% CI 74.5–76.4%)	96.2% (95% CI 96.0 – 96.4%)
Mykrobe	71.9% (95% CI 70.9–72.9%)	97.6% (95% CI 97.5–97.7%)
TB-Profiler	74.4% (95% CI 73.4–75.3%)	96.9% (95% CI 96.7 to 97.0%)

- Trade-off between specificity and sensitivity
- Low sequencing depth data: lower sensitivity (the need for quality control)

(Gröschel et al, 2021)

#### Advantages:

- Captures both common and rare mutations
- Multivariate prediction models:
  - Gene-gene interaction
- Higher sensitivity but slightly lower specificity

#### **Limitations**:

-Short-read sequencing lowers the sensitivity in detecting genomic variants (e.g. structural variation).

-Does not cover recently introduced or repurposed drugs.

-Does not re-test the laboratory-based drug susceptibility profiles for isolates with discordant predictions

-Diagnostic accuracy maybe vary among datasets from different countries.

#### S3: Opportunities and challenges

# Challenges

- 1. Data availability:
  - 1) Class-imbalance

e.g. more antibiotic-susceptible isolates than resistant isolates

2) New antibiotic

4) Data sharing (e.g. FDA-ARGOS database)

- 2. Risk of overfitting
- 3. Understanding of AMR mechanisms

e.g. complex AMR mechanisms

# **Opportunities:**

- 1. Reduced cost of WGS
- 2. Improvements in bioinformatic software
- 3. Continued growth of data and research interest
- 4. Providing more profound insight into the mechanisms of AMR
- 5. Providing organism identification, and information on virulence factors

#### **Reference**:

ANAHTAR, M. N., YANG, J. H. & KANJILAL, S. 2021. Applications of machine learning to the problem of antimicrobial resistance: an emerging model for translational research. *Journal of clinical microbiology*, 59, e01260-20.
 CENTERS FOR DISEASE CONTROL AND PREVENTION. 2021. *Antimicrobial resistance* [Online]. Available: <a href="https://www.cdc.gov/drugresistance/index.html">https://www.cdc.gov/drugresistance/index.html</a> [Accessed].

- CHEN, M. L., DODDI, A., ROYER, J., FRESCHI, L., SCHITO, M., EZEWUDO, M., KOHANE, I. S., BEAM, A. & FARHAT, M. 2019. Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction. *EBioMedicine*, 43, 356-369.
- FARHAT, M. R., SULTANA, R., IARTCHOUK, O., BOZEMAN, S., GALAGAN, J., SISK, P., STOLTE, C., NEBENZAHL-GUIMARAES, H., JACOBSON, K. & SLOUTSKY, A. 2016. Genetic determinants of drug resistance in Mycobacterium tuberculosis and their diagnostic value. *American journal of respiratory and critical care medicine*, 194, 621-630.
- GRÖSCHEL, M. I., OWENS, M., FRESCHI, L., VARGAS, R., MARIN, M. G., PHELAN, J., IQBAL, Z., DIXIT, A. & FARHAT, M. R. 2021. GenTB: A user-friendly genome-based predictor for tuberculosis resistance powered by machine learning. *Genome medicine*, 13, 1-14.
- LI, Y. & CHEN, Z. 2018. Performance evaluation of machine learning methods for breast cancer prediction. *Appl Comput Math*, 7, 212-216.
- LV, J., DENG, S. & ZHANG, L. 2021. A review of artificial intelligence applications for antimicrobial resistance. *Biosafety and Health*, 3, 22-31.

# Thank you!

Q & A